In addition, simultaneous inhibition of adenosine production (e.g. by an anti-CD73 antibody, mupadolimab) and receptor binding (e.g. by an A2AR antagonist, ciforadenant) has also demonstrated its potential synergy, and is under investigation among multiple advanced cancers in the clinic (NCT03454451) (Fig. 3). This evidence concerns the gene NT5E and cancer.